Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

Table 4

Relative risk reductions (RRRs) of efficacy outcome event rates versus VKA control groups.

	RE-LY [21]		ROCKET AF [14]	ARISTOTLE [15]
	Dabigatran 110 mg BD	Dabigatran 150 mg BD	Rivaroxaban	Apixaban
Primary outcome RRR, %	↓ 10*	↓ 35*	↓ 21*	↓ 21*
Haemorrhagic stroke RRR, %	↓ 69*	↓ 74*	↓ 41*	↓ 49*
Ischaemic/unknown stroke RRR, %	↑ 11	↓ 24*	↓ 6	↓ 8
CV death RRR, %	↓ 10	↓ 15*	↓ 11	↓ 11
All death RRR, %	↓ 9	↓ 12	↓ 15	↓ 11*
MI RRR, %	↑ 29	↑ 27	↓ 19	↓ 12

BD: twice daily; RRR: relative risk reduction.
* P < 0.05.